Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21685747 | 0.93 | PDE4B (0.44) | MEN1KMT2ASYKCTSLL3MBTL1 | |
| SCHEMBL5270018 | 0.87 | ALDH1A1 (0.42) | HSD11B1CTSLCTSBCTSKALDH1A1 | |
| SCHEMBL743504 | 0.87 | ALDH1A1 (0.42) | HSD11B1CTSLCTSBCTSKALDH1A1 | |
| SCHEMBL764743 | 0.85 | ABCB1 (0.39) | BACE1HSD11B1STSMEN1KMT2A | |
| SCHEMBL23274789 | 0.82 | STS (0.44) | STSMEN1KMT2ASYKCTSL | |
| SCHEMBL31721977 | 0.82 | STS (0.44) | STSMEN1KMT2ASYKCTSL | |
| SCHEMBL31722357 | 0.82 | STS (0.44) | STSMEN1KMT2ASYKCTSL | |
| SCHEMBL19123019 | 0.82 | SYK (0.43) | HSD11B1STSMEN1KMT2ASYK | |
| SCHEMBL21685513 | 0.81 | PDE4B (0.42) | MEN1KMT2ASYKCTSLL3MBTL1 | |
| SCHEMBL21685549 | 0.81 | PDE4B (0.42) | MEN1KMT2ASYKCTSLL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729063-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729063-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-8362003-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362003-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2431357-A2 | 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors | Incyte Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2011-10-13 | — | — | US | disclosed |
| US-7985730-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-7834021-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834021-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | INCYTE CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | BACE1 4279/4885HSD11B1 3197/4885STS 3948/4885 |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | BACE1 4134/4885HSD11B1 3098/4885STS 3918/4885 |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | CCR2, CXCR3, CCR5 | BACE1 4279/4885HSD11B1 3197/4885STS 3948/4885 |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | BACE1 4279/4885HSD11B1 3197/4885STS 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.